Skip to main content
Caplight Logo









Autoimmunity BioSolutions

Autoimmunity BioSolutions

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.abstherapeutics.com/

Last Round

Seed

May 6, 2026

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Autoimmunity BioSolutions is a biotechnology company developing a next-generation, immuno-corrective antibody therapy for the treatment of autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

monoclonal antibodiesautoimmune disease therapymAbsantibody therapeuticsimmune tolerancebiologicspreclinical biotechdrug discoverybiopharmaT cell modulationanti-CD6drug licensingpharma partnershipsantisense oligonucleotideASONIH SBIR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Autoimmunity BioSolutions Comparables

Compare Autoimmunity BioSolutions with similar companies based on industry and business-model similarity.

Autoimmunity BioSolutions comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AbolerIS Pharma
78%
Anokion
76%
Equillium Inc.
76%

Autoimmunity BioSolutions Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 6, 2026

Key People

Founding team and executive leadership

Thomas Forest Farb-Horch

CEO, President And Board Member At Thrive Bioscience, Inc.

Executive Team

Autoimmunity BioSolutions Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors increased 1646% MoM, reaching 1.2K.

  • May 6, 2026

    Raised $3.2M in Seed funding.

Autoimmunity BioSolutions Filings

Explore SEC and related filing metadata, where available.

Autoimmunity BioSolutions filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Autoimmunity BioSolutions's valuation, stock price, and market status.

Is Autoimmunity BioSolutions a public or private company?

Autoimmunity BioSolutions is a private company.

What is the current stock price of Autoimmunity BioSolutions?

Autoimmunity BioSolutions is a private company with no public stock price. No recent secondary market data is available.

How much is Autoimmunity BioSolutions worth (valuation)?

Valuation information for Autoimmunity BioSolutions is not publicly available.

Can I buy Autoimmunity BioSolutions stock?

Autoimmunity BioSolutions shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Autoimmunity BioSolutions's last funding round?

Autoimmunity BioSolutions's most recent funding round was Seed on May 6, 2026.

Who are the main investors in Autoimmunity BioSolutions?

Key investors in Autoimmunity BioSolutions include Eos.

Will Autoimmunity BioSolutions IPO soon?

No public IPO plans have been announced for Autoimmunity BioSolutions.

How can I track Autoimmunity BioSolutions secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Autoimmunity BioSolutions's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range2
Year Founded2016
Last FundingMay 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?